Last reviewed · How we verify
Shenlingcao Oral Liquid
Shenlingcao Oral Liquid, marketed by West China Hospital, is a traditional Chinese medicine with a complex herbal composition. Its key strength lies in its potential immunomodulatory effects, which differentiate it in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition.
At a glance
| Generic name | Shenlingcao Oral Liquid |
|---|---|
| Also known as | placebo of Shenlingcao Oral Liquid |
| Sponsor | West China Hospital |
| Drug class | Traditional Chinese Medicine |
| Target | Immune system |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC (PHASE4)
- The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue (PHASE2)
- Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shenlingcao Oral Liquid CI brief — competitive landscape report
- Shenlingcao Oral Liquid updates RSS · CI watch RSS
- West China Hospital portfolio CI